First Trust Advisors LP Apellis Pharmaceuticals, Inc. Transaction History

First Trust Advisors LP

$108 Billion
Q4 2024

A detailed history of First Trust Advisors LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 25,645 shares of APLS stock, worth $622,404. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,645

Previous 17,301 48.23%

Holding current value

$622,404

Previous $498,000 64.26%

% of portfolio

0.0%

Previous 0.0%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$26.18 - $35.42 $218,445 - $295,544	8,344 Added 48.23%	25,645 $818,000
Q3 2024 Nov 13, 2024	SELL	$28.84 - $41.15 $3.07 Million - $4.38 Million	-106,424 Reduced 86.02%	17,301 $498,000
Q2 2024 Aug 13, 2024	SELL	$38.07 - $59.71 $10.8 Million - $16.9 Million	-282,758 Reduced 69.56%	123,725 $4.75 Million
Q1 2024 May 13, 2024	BUY	$55.39 - $72.47 $17.3 Million - $22.6 Million	312,515 Added 332.58%	406,483 $23.9 Million
Q4 2023 Feb 13, 2024	SELL	$37.14 - $64.82 $11.3 Million - $19.7 Million	-304,170 Reduced 76.4%	93,968 $5.62 Million
Q3 2023 Nov 13, 2023	BUY	$23.65 - $89.22 $7.59 Million - $28.6 Million	320,847 Added 415.12%	398,138 $15.1 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $2.22 Million - $2.7 Million	28,969 Added 59.95%	77,291 $7.04 Million
Q1 2023 May 15, 2023	SELL	$46.59 - $66.96 $207,698 - $298,507	-4,458 Reduced 8.45%	48,322 $3.19 Million
Q4 2022 Feb 09, 2023	BUY	$43.24 - $61.04 $1.19 Million - $1.68 Million	27,551 Added 109.2%	52,780 $2.73 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $1.71 Million - $2.67 Million	-38,296 Reduced 60.28%	25,229 $1.72 Million
Q2 2022 Aug 12, 2022	BUY	$35.07 - $59.21 $200,460 - $338,444	5,716 Added 9.89%	63,525 $2.87 Million
Q1 2022 May 13, 2022	BUY	$35.46 - $54.12 $2.05 Million - $3.13 Million	57,809 New	57,809 $2.94 Million
Q2 2020 Jul 22, 2020	SELL	$24.8 - $38.49 $1.42 Million - $2.21 Million	-57,356 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$17.91 - $44.33 $228,746 - $566,182	-12,772 Reduced 18.21%	57,356 $1.54 Million
Q4 2019 Feb 03, 2020	BUY	$22.1 - $30.8 $91,096 - $126,957	4,122 Added 6.24%	70,128 $2.15 Million
Q3 2019 Nov 04, 2019	BUY	$24.09 - $32.18 $1.59 Million - $2.12 Million	66,006 New	66,006 $1.59 Million

Others Institutions Holding APLS

# of Institutions

300

Shares Held

111M

Call Options Held

2.63M

Put Options Held

845K

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $2.67B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.

Account

First Trust Advisors LP Apellis Pharmaceuticals, Inc. Transaction History